Physician profile
Keith Whitmer
NPI 1467414235
$20,533.06
in general payments reported to CMS, 2019-2025
50 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,802 · 2020: $2,010 · 2021: $2,966 · 2022: $4,186 · 2023: $2,815 · 2024: $2,744 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,322 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,321.79 |
| Education | $246.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,278.75 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Regeneron Healthcare Solutions, INC. | $2,298.65 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $1,856.25 | 2019-2025 | Oracea, Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $1,627.31 | 2019-2025 | |
| Janssen Biotech, INC. | $1,131.00 | 2019-2025 | Tremfya, Stelara, Remicade |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,049.13 | 2019-2025 | Siliq, Arazlo, Jublia |
| Leo Pharma INC. | $876.97 | 2019-2025 | Adbry |
| Genzyme Corporation | $865.30 | 2019-2025 | |
| Amgen INC. | $708.53 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $702.18 | 2019-2024 | Odomzo, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $602.39 | 2022-2025 | Sotyktu |
| Pfizer INC. | $546.87 | 2019-2025 | |
| Ucb, INC. | $505.06 | 2019-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $395.17 | 2019-2025 | Cygnus Dual, Puraply |
| Incyte Corporation | $388.25 | 2021-2024 | Opzelura |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $354.72 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $351.61 | 2019-2022 | |
| Celgene Corporation | $304.53 | 2019 | |
| Lilly USA, LLC | $299.50 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Vyne Pharmaceuticals INC. | $232.77 | 2020-2021 | |
| Dermavant Sciences, INC. | $213.38 | 2022-2024 | Vtama |
| Dusa Pharmaceuticals, INC. | $178.08 | 2019 | |
| Mayne Pharma Commercial LLC | $172.24 | 2019-2025 | |
| Aclaris Therapeutics, INC. | $164.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $158.06 | 2019-2020 | |
| Almirall LLC | $146.57 | 2019-2021 | |
| Strata Skin Sciences, INC. | $126.29 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $119.22 | 2025 | Zoryve |
| Epi Health, LLC | $116.83 | 2019-2021 | |
| Sandoz INC. | $108.93 | 2019-2020 | |
| Sensus Healthcare, INC. | $108.76 | 2019 | |
| Genentech USA, INC. | $105.90 | 2019-2021 | |
| Convatec INC. | $60.32 | 2023-2024 | |
| Botanix Sb INC | $49.01 | 2025 | Sofdra |
| Biofrontera INC. | $40.46 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Kerecis Limited | $30.32 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.02 | 2024 | Spevigo |
| Acera Surgical, INC. | $25.70 | 2022 | |
| Lnhc, INC | $22.38 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $22.00 | 2024 | Ycanth |
| Integra Lifesciences Corporation | $21.84 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Fresenius Kabi USA, LLC | $20.98 | 2023 | |
| Cipher Pharmaceuticals US LLC | $19.43 | 2025 | Spinosad, Natroba |
| Mimedx Group, INC. | $18.99 | 2024 | |
| Organon LLC | $17.12 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $15.30 | 2025 | Nuzyra |
| Promius Pharma LLC | $12.45 | 2019 | |
| Encore Dermatology INC. | $12.04 | 2020 | |
| Allergan, INC. | $11.84 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Whitmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.